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ABSTRACT
Background Therapeutic targets have been deﬁned for
diseases like diabetes, hypertension or rheumatoid
arthritis and adhering to them has improved outcomes.
Such targets are just emerging for spondyloarthritis
(SpA).
Objective To deﬁne the treatment target for SpA
including ankylosing spondylitis and psoriatic arthritis
(PsA) and develop recommendations for achieving the
target, including a treat-to-target management strategy.
Methods Based on results of a systematic literature
review and expert opinion, a task force of expert
physicians and patients developed recommendations
which were broadly discussed and voted upon in a
Delphi-like process. Level of evidence, grade and
strength of the recommendations were derived by
respective means. The commonalities between axial SpA,
peripheral SpA and PsA were discussed in detail.
Results Although the literature review did not reveal
trials comparing a treat-to-target approach with another
or no strategy, it provided indirect evidence regarding an
optimised approach to therapy that facilitated the
development of recommendations. The group agreed on
5 overarching principles and 11 recommendations; 9 of
these recommendations related commonly to the whole
spectrum of SpA and PsA, and only 2 were designed
separately for axial SpA, peripheral SpA and PsA. The
main treatment target, which should be based on a
shared decision with the patient, was deﬁned as
remission, with the alternative target of low disease
activity. Follow-up examinations at regular intervals that
depend on the patient’s status should safeguard the
evolution of disease activity towards the targeted goal.
Additional recommendations relate to extra-articular and
extramusculoskeletal aspects and other important factors,
such as comorbidity. While the level of evidence was
generally quite low, the mean strength of
recommendation was 9–10 (10: maximum agreement) for
all recommendations. A research agenda was formulated.
Conclusions The task force deﬁned the treatment
target as remission or, alternatively, low disease activity,
being aware that the evidence base is not strong and
needs to be expanded by future research. These
recommendations can inform the various stakeholders
about expert opinion that aims for reaching optimal
outcomes of SpA.
The approaches to the diagnosis, therapy and
follow-up of patients with ankylosing spondylitis
(AS) and psoriatic arthritis (PsA) have undergone a
number of paradigmatical changes over the last
decade. Especially considerations of the disease
spectrum of spondyloarthritis (SpA) have recently
undergone remarkable changes. In addition to AS,
deﬁned by prevalent radiographic structural
changes in the sacroiliac joints, non-radiographic
axial SpA (axSpA) has been deﬁned based on the
absence of such changes but presence of sacroiliitis
(as documented by MRI) and/or human leukocyte
antigen B27. The term axSpA, therefore, includes
radiographic axSpA (AS) and non-radiographic
axSpA. On this basis, new classiﬁcation criteria
have been established by Assessment of
SpondyloArthritis international Society (ASAS),1
novel therapies have proven efﬁcacious,2–6 MRI has
been increasingly established as an imaging tool in
SpA1 7 8 and new indices to assess disease activity
have been developed.9–14 The novel approach to
classiﬁcation has also differentiated the two pre-
dominant manifestations of SpA, axial and/or per-
ipheral, and their potential parallel occurrence.15
The basis for the new classiﬁcation lies in the
sharing of characteristic features of SpA, such as
sacroiliitis, spondylitis and enthesitis and common
genetic markers and a positive family history.
Furthermore, extramusculoskeletal manifestations
such as psoriasis in PsA, a preceding gastrointestinal
or urogenital infection as in the case of reactive
arthritis (ReA), and chronic inﬂammatory bowel
diseases (IBD) like Crohn’s disease and ulcerative
colitis, play a role in the deﬁnition of a clinical
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syndrome as belonging to the concept of SpA. For the classiﬁca-
tion of patients with PsA the Classiﬁcation Criteria for Psoriatic
Arthritis (CASPAR) criteria are well established.16 Since the
presence of psoriasis plays a role in both criteria sets, the ASAS
and the CASPAR criteria, there is some overlap between the
two. There is no international agreement whether and how they
can or should be differentiated. Finally, to account for thera-
peutic developments, management recommendations have
recently been presented.17–20
Despite all these advances, a variety of challenges exist when
considering the management of patients with SpA,21–24 not least
because the deﬁnition of a clear therapeutic target and strategies
to reach such target are not yet optimally deﬁned.
In many areas of medicine, such as diabetes care or cardi-
ology, clear therapeutic targets are available.25–30 More recently,
a treatment target has also been advocated for rheumatoid arth-
ritis (RA), namely remission or low disease activity,31 32 a rec-
ommendation based on insights from various clinical trials as
revealed by systematic literature reviews (SLRs).33 34 Much less
information on the value of deﬁning therapeutic targets is cur-
rently available for AS or PsA. Therefore, a task force was
formed to discuss and develop a consensus on recommendations
aimed at deﬁning a treatment target for, and thus at improving
the management of axial and peripheral SpA in clinical practice.
METHODS
The consensus ﬁnding consisted of a three-step process. In a ﬁrst
step, the ﬁrst and last author invited leading experts, deﬁned on
the basis of their citation frequency in the ﬁeld and previous con-
tributions to similar activities to form a steering committee. This
steering committee, which included rheumatologists experienced
in the care of patients with, and/or clinical research in axial and/
or peripheral SpA (several of them Department chairs and thus
in managerial functions), a dermatologist experienced in psoria-
sis, and patients being diagnosed with one of these diseases and/
or experienced in consensus ﬁnding processes, met in March
2011 in Vienna to discuss unmet needs in the therapeutic man-
agement of and the potential of using treatment targets in AS and
PsA. To this end, the debate focused on axial and peripheral SpA
separately in two breakout groups with a subsequent common
assessment. In the course of these discussions there was unani-
mous agreement that deﬁning therapeutic targets and an appro-
priate strategic treatment approach would be valuable, but that
evidence for its validity may be lacking. Therefore it was decided
to perform a SLR and respective PICO (Patient, Intervention,
Control, Outcome) and search terms were formulated, in line
with European League Against Rheumatism (EULAR) and
Appraisal of Guidelines for Research and Evaluation recommen-
dations.35 36 In the course of deﬁning the scope of this activity,
the target populations were also speciﬁed, namely health profes-
sionals involved in care of and patients affected by axial and/or
peripheral SpA. In addition, social security ofﬁcials, hospital
managers and policy makers at national and international levels
were considered potential stakeholders in this activity.
At a subsequent meeting in November 2011 (Dusseldorf)
comprising an expanded task force with increased international
participation, the SLR was presented. These invitations were a
consequence of the individuals’ contributions to the ﬁeld and
deliberations among members of the steering committee. The
literature search had revealed that currently no strategic trials
addressing a target-oriented, steered therapy were published,
although some indirect evidence on optimal therapeutic
approaches was available to inform the next stages of the
process.37 A major focus of discussion at this meeting, but also
already at the steering committee meeting, was the question if
diseases like AS, PsA, ReA and IBD arthritis should be seen as
an entity or as different diseases. The respective decision would
have a bearing to the consensus ﬁnding process, since it would
mean to develop one, two or more documents. The initial delib-
erations tended toward separating the individual diseases for
several reasons: (1) despite many commonalities, some import-
ant clinical manifestations are distinct between these conditions
and certain health professionals (such as dermatologists and gas-
troenterologists) may not be sufﬁciently aware of the more uni-
fying concept of SpA or its relevance when dealing with these
conditions; (2) further, the existing distinction between PsA and
AS is well known for and accepted by patients and changes in
terminology may cause confusion regarding the understanding
of their ‘new’ diagnosis; (3) to date, clinical trials have been per-
formed almost entirely in individual subentities (AS, PsA) rather
than SpA, and even most recently trials in a highly speciﬁc novel
subset, non-radiographic axSpA, have been performed38; (4) the
current drug approval process by regulatory agencies is also
related to the individual diseases rather than SpA; and (5) there
is some overlap between the different subgroups, but there are
also major distinctions, for example, PsA with symmetric polyar-
thritis as the predominant feature would not ﬁt well into either
the axial or peripheral SpA group. Therefore, the provisional
choice was to develop at least two documents, one for axSpA
and one for PsA. The discussions took place in separate break-
out sessions devoted to these topics and in a plenary session. At
the plenary session, certain items were reformulated and reor-
dered and two provisional sets of recommendations developed,
with decisions made using a modiﬁed Delphi technique.32 The
group then realised how similar the individual statements in
each of the two documents were, but left further decisions to
the next stage of the process.
With these two documents prepared and having in mind that
peripheral SpA (such as ReA) had not yet been dealt with in
detail, an even larger committee met in April 2012
(Amsterdam); its membership comprised the initial task force
expanded by consideration of a more international scope to also
include experts from Latin America and Asia, aside from previ-
ous participants from Europe and North America. Again, the
scope and background of this activity was discussed and the pro-
visional recommendations presented. The issue of disease deﬁn-
ition and the need of developing one, two or three documents
were addressed. The committee separated into three breakout
groups discussing axSpA, peripheral SpA and PsA. In the course
of the breakout discussions and the plenary session, the initial
recommendations were amended and then votes cast.
Importantly, when looking at the individual items, the partici-
pants felt that most of them were very similar and a broad deci-
sion was then taken to develop a single document comprising
overarching principles and items common to SpA in general,
but within that common document to develop a few individua-
lised items for axSpA, PsA and peripheral SpA.
Each statement, which had been formulated as a draft for
voting in the course of the breakout sessions and by the whole
task force, was subjected to voting as ‘yes’ (agreement with the
wording) or ‘no’ (disagreement). Statements supported by
≥75% of votes were immediately accepted while those with
≤25% were rejected outright. Others were subjected to further
discussion and subsequent voting, where ≥67% support or, in
an eventual third round, a majority of ≥50% was needed.
After the face-to-face meeting, the statements were distributed
to the committee members by email for ﬁnal comments. Only
suggestions for improvements of clarity of wording or
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addressing redundancies were considered, while any changes to
the meaning were not accepted.
Finally, the group voted anonymously by email on the level of
agreement, that is, strength of recommendation, with each of
the derived bullet points (in the form it was ultimately agreed
upon by the qualiﬁed majority of participants) using a 10-point
numerical rating scale (1=do not agree at all, 10=agree
completely).
RESULTS
The evidence base
The SLR, which is published separately,37 revealed that in con-
trast to ﬁndings in RA33 no randomised controlled clinical trial
has evaluated a targeted therapeutic approach in comparison
with routine therapy. However, several publications had
employed therapeutic targets and respective time requirements
as endpoints or before escalating therapy, although this is often
the placebo arm of a study that was allowed to escape or then
escalated to active treatment. These comprised 14 studies in AS
and 7 studies of PsA which were found suitable to inform the
task force. Nevertheless, given the lack of studies evaluating
target-steered versus non-steered treatment, the level of evidence
for the developed recommendations is low and mainly based on
expert consensus.
The consensus
The individual statements receiving a positive vote by the major-
ity of the expert committee members comprise 5 overarching
principles and 11 recommendations. The overarching principles
and 9 of the statements are recommended for SpA in general,
whereas the last 2 statements have been individualised for
axSpA, peripheral SpA and PsA. The recommendations are
shown in table 1. They are discussed in detail below and this
detailed description should be regarded as part and parcel of
the recommendations.
Overarching principles
In the Committee’s view, a number of elements related to treat-
ing SpA are so representative of good clinical practice that they
form a general framework for more speciﬁc recommendations.
These were therefore termed overarching principles, and ﬁve
such principles were developed and voted on.
A. The treatment target must be based on a shared decision
between patient and rheumatologist.
Patient involvement in therapeutic decision-making has
become a mandate in patient care, especially when dealing with
chronic diseases. This is a general patient right, and has been
shown to improve mutual understanding and outcome39–42 and
is also increasingly recognised to be important in SpA.43–45 The
committee was convinced that patients must be informed about
the proposed treatment target, therapeutic options to reach the
target and reasons for recommending the target also in light of
the risk related to treatment and risk related to the disease; on
the other hand, patients should actively participate in this dis-
cussion. This aspect is subsequently reinforced in recommenda-
tion number 8 and these two items received the highest level of
agreement among all bullet points. The principle also speciﬁc-
ally mentions the rheumatologist, since it is the rheumatologist
who should coordinate treatment of patients with SpA.
Evidence regarding RA suggests that patient outcome is better
when care is provided by a rheumatologist,46 and this might
also be so for the musculoskeletal manifestations of PsA and
SpA.
B. SpA and PsA are often complex systemic diseases; as
needed, the management of musculoskeletal and extra-articular
manifestations should be coordinated between the rheumatolo-
gist and other specialists (such as dermatologist, gastroenterolo-
gist, ophthalmologist).
This item is supposed to inform patients, healthcare profes-
sionals with less experience in the care of SpA and non-medical
stakeholders that patients with SpA are frequently suffering
from extramusculoskeletal manifestations and are often in need
of multidisciplinary care for optimal therapy. When multiorgan
involvement is present, a harmonised approach among specia-
lists is required which should ideally be coordinated by the
rheumatologist, especially if the musculoskeletal involvement
causes major complaints.
C. The primary goal of treating the patient with SpA and/or PsA
is to maximise long-term health related quality of life and social
participation through control of signs and symptoms, prevention
of structural damage, normalisation or preservation of function,
avoidance of toxicities and minimisation of comorbidities.
The signiﬁcant burden of axSpA and PsA in terms of disabil-
ity, loss of quality of life and work productivity has only
recently been appreciated.47–52 This generally formulated item
addresses the importance to control signs and symptoms like
pain, structural changes such as ankylosis,53 54 comborbid-
ities55–57 and the importance of focusing on the totality of
disease manifestations and complications when determining the
proposal for a treatment target.
D. Abrogation of inﬂammation is presumably important to
achieve these goals.
PsA and SpA are inﬂammatory diseases and inﬂammation
leads to their signs and symptoms, functional impairment as
well as structural changes.7 11 58–61 Therefore, stopping inﬂam-
mation appears to be of key importance to optimise outcome.
Indeed, in many patients non-steroidal anti-inﬂammatory drugs
(NSAIDs) can lead to cessation of signs and symptoms, normal-
isation of physical function and potentially inhibition of struc-
tural damage in the spine.62 63 Interference with the
proinﬂammatory cytokine tumour necrosis factor (TNF) sup-
presses inﬂammation effectively and can lead to disappearance
of signs and symptoms and maximal improvement of physical
function. Thus, the task force was convinced that disappearance
of inﬂammation conveys the best outcome. However, current
evidence indicates that TNF inhibition does not prevent pro-
gression of structural changes in AS.64 65 Moreover, it has not
been determined if a state of remission leads to better long-term
outcome of SpA and/or PsA than low disease activity. Thus, this
item is somewhat more controversial than most other ones.
Therefore the word ‘presumably’ was added. This point consti-
tutes a backbone for some of the subsequent individual
recommendations.
E. Treatment to target by measuring disease activity and
adjusting therapy accordingly contributes to the optimisation of
short and/or long-term outcomes.
The SLR has revealed that patients with AS who do not reach
predeﬁned, measurable treatment targets can achieve further
improvement upon adaptation of their therapy. While for PsA
this has not yet been established, the task force regarded the need
to measure disease activity and amend therapy with persistently
active disease as a general necessity and, therefore, as a principle.
The level of agreement with these ﬁve principles was very
high, ranging between 9.1 (item D) and 9.7 (item A) on a scale
of 10 (table), indicating that this large and quite heterogeneous
task force had arrived at a quite unanimous view on the princi-
pal importance of certain approaches to treatment of SpA.
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Recommendations
As mentioned previously, after intensive deliberations the com-
mittee had decided to create just one document covering axial
and peripheral SpA, including PsA. To this end, nine uniﬁed
recommendations and two additional items dealing separately
with PsA, axial SpA and peripheral SpA were developed in the
course of the discussions. These recommendations applied the
results of the SLR, but given the low available evidence in the
literature, they were mostly based on expert opinion, albeit con-
sensual opinions of a large group of experts. The sequence of
the recommendations follows a logical order, but also reﬂects
the level of importance considered by the committee for each
individual bullet point.
Common recommendations
1. A major treatment target should be clinical remission/inactive
disease of musculoskeletal involvement (arthritis, dactylitis,
enthesitis, axial disease), taking extra-articular manifestations
into consideration (level of evidence (LoE): 5, grade of recom-
mendation (GoR): D).
Hitherto, no clinical trial has compared outcomes of PsA or
axSpA for progression of structural changes or improvement of
physical function or quality of life when remission rather than
another state was targeted. Deﬁnitions for remission (which is
called inactive disease in AS) or at least minimal disease activity
(MDA) exist for PsA and AS,12 66 67 but in contrast to RA the
long-term beneﬁts of remission have not yet been sufﬁciently
Table 1 Recommendations to treat all forms of Spondyloarthritis to target
LoE GoR SoR
Overarching principles
A. The treatment target must be based on a shared decision between patient and rheumatologist 5 D 9.7±0.8
B. SpA and PsA are often complex systemic diseases; as needed, the management of musculoskeletal and extra-articular manifestations
should be coordinated between the rheumatologist and other specialists (such as dermatologist, gastroenterologist, ophthalmologist)
5 D 9.5±0.92
C. The primary goal of treating the patient with SpA and/or PsA is to maximise long-term health related quality of life and social
participation through control of signs and symptoms, prevention of structural damage, normalisation or preservation of function,
avoidance of toxicities and minimisation of comorbidities
5* D 9.6±0.67
D. Abrogation of inflammation is presumably important to achieve these goals 5* D 9.1±1.04
E. Treatment to target by measuring disease activity and adjusting therapy accordingly contributes to the optimisation of short term and/
or long term outcomes
5* D 9.2±1.11
Recommendations
Common items for all forms of SpA
1. A major treatment target should be clinical remission/inactive disease of musculoskeletal involvement (arthritis, dactylitis, enthesitis,
axial disease), taking extra-articular manifestations into consideration
5* D 9.5±0.77
2. The treatment target should be individualised according to the current clinical manifestations of the disease 5 D 9.3±1.03
3. Clinical remission/inactive disease is defined as the absence of clinical and laboratory evidence of significant inflammatory disease
activity
5 D 9.0±1.41
4. Low/minimal disease activity may be an alternative treatment target 5* D 9.4±0.91
5. Disease activity should be measured on the basis of clinical signs and symptoms, and acute phase reactants 5* D 9.4±1.14
6. The choice of the measure of disease activity and the level of the target value may be influenced by considerations of comorbidities,
patient factors and drug-related risks
5 D 9.4±1.02
7. Once the target is achieved, it should ideally be maintained throughout the course of the disease 5* D 9.4±0.76
8. The patient should be appropriately informed and involved in the discussions about the treatment target, and the risks and benefits of
the strategy planned to reach this target
5 D 9.8±0.50
9. Structural changes, functional impairment, extra-articular manifestations, comorbidities and treatment risks should be considered when
making clinical decisions, in addition to assessing measures of disease activity
5 D 9.5±0.81
Specific items for individual types of Spondyloarthritis
Axial Spondyloarthritis (including ankylosing spondylitis)
10. Validated composite measures of disease activity such as the BASDAI plus acute phase reactants or the Ankylosing Spondylitis Disease
Activity Score, with or without measures of function such as BASFI, should be performed and documented regularly in routine clinical
practice to guide treatment decisions; the frequency of the measurements depends on the level of disease activity
5 D 9.3±0.95
11. Other factors, such as axial inflammation on MRI, radiographic progression, peripheral musculoskeletal and extra-articular
manifestations, as well as comorbidities may also be considered when setting clinical targets
5* D 9.3±0.80
Peripheral Spondyloarthritis
10. Quantified measures of disease activity, which reflect the individual peripheral musculoskeletal manifestations (arthritis, dactylitis,
enthesitis) should be performed and documented regularly in routine clinical practice to guide treatment decisions; the frequency of the
measurements depends on the level of disease activity
5 D 9.3±0.85
11. Other factors. such as spinal and extra-articular manifestations, imaging results, changes in function/quality of life, as well as
comorbidities may also be considered for decision
5 D 9.4±0.78
Psoriatic arthritis
10. Validated measures of musculoskeletal disease activity (arthritis, dactylitis, enthesitis, axial disease) should be performed and
documented regularly in routine clinical practice to guide treatment decisions; the frequency of the measurements depends on the level
of disease activity; cutaneous manifestations should also be considered
5 D 9.4±0.78
11. Other factors, such as spinal and extra-articular manifestations, imaging results, changes in function/quality of life, as well as
comorbidities may also be considered for decision
5 D 9.3±1.00
An asterisk in the LoE column denotes that for this item indirect evidence is available from the literature search which was nevertheless not sufficient for a higher grading of the
evidence level.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; GoR, grade of recommendation; LoE, level of evidence; PsA, psoriatic
arthritis; SoR, strength of recommendation (level of agreement); SpA, spondyloarthritis.
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established. Also, no clear deﬁnition of remission for extra-
articular musculoskeletal features, such as enthesitis or dactylitis,
is currently available. Moreover, it is not sufﬁciently known at
present how remission of musculoskeletal symptoms relates to
remission of skin disease in PsA or bowel disease in IBD.
Therefore, the formulation of this ﬁrst bullet point reﬂects the
general lack of data, by saying ‘a major’ rather than ‘the major’
treatment goal, or by expanding the term ‘clinical remission’ to
the somewhat less stringent term ‘inactive disease’. However,
the lack of thorough evidence and the unwillingness of the
group to arrive at a more determined and clear verbalisation of
this bullet point must not be mistaken as an uncertainty of the
task force regarding the necessity of treating patients to become
free of signs and symptoms of their peripheral joint or axial
disease. On the contrary, the task force deemed this approach to
be of utmost importance for short-term beneﬁt and long-term
outcome. Therefore it was placed as the ﬁrst recommendation.
Importantly, the group focussed the terms ‘remission’/‘inactive
disease’ to the musculoskeletal manifestations of SpA and not
the extramusculoskeletal abnormalities, although it clearly stated
in the last part of this item that this must not be neglected in
the therapeutic decision making. After several rounds of discus-
sion, 83% of the participants agreed with the formulation of
this bullet point and the strength of recommendation amounted
to 9.5±0.9.
2. The treatment target should be individualised according to the
current clinical manifestations of the disease (LoE: 5, GoR: D)
This item emphasises that every patient should be treated
according to her or his current clinical manifestations and that
in light of their heterogeneity each of these manifestations has
to be accounted for when setting the therapeutic target.
However, it also implies that at certain points in time the mus-
culoskeletal symptoms may not be in the foreground, such as
when extra-articular manifestations prevail and need appropri-
ate attention. Again, no data exist in the literature to support or
refute this recommendation which was voted for by 87% of the
participants and attained a strength of recommendation (SoR)
of 9.3±1.0.
3. Clinical remission/inactive disease is deﬁned as the absence
of clinical and laboratory evidence of signiﬁcant inﬂammatory
disease activity.
This bullet point provides a deﬁnition for item 1 in order to
clarify the deﬁnition of remission. Remission of an inﬂammatory
rheumatic disease ideally comprises the absence of its signs and
symptoms, the maximal improvement in physical function and
halt of structural changes. While there is compelling evidence
that these three characteristics go along with each other in RA,
this is not yet sufﬁciently known in AS and PsA. However, in
PsA, progression of joint damage is correlated with swollen joint
counts and dactylitis59 68 and, therefore, it may be assumed that
clinical remission will also lead to halt of structural progression.
This is not quite clear in AS, since progression of syndesmo-
phyte formation has been observed even when patients were in
clinical remission on TNF inhibitors and formation of syndes-
mophytes occurred without presence of MRI inﬂamma-
tion.8 64 65 69 On the other hand, elevated levels of acute phase
reactants (APRs) are associated with progression of structural
changes in AS.70 Further, physical function and quality of life
are related to symptoms of these diseases.71 For all these reasons
the task force deﬁned remission as stated above. Deﬁnitions of
remission or partial remission are available for AS, when using
mere patient reported outcomes67 or the more recently
described Ankylosing Spondylitis Disease Activity Score
(ASDAS).12 For PsA, remission criteria are not well
established,66 especially given that in PsA most composite mea-
sures have been borrowed from RA while a composite measure
speciﬁc for PsA has only recently been validated,10 but criteria
for disease activity states have not yet been deﬁned. Importantly,
the term ‘signiﬁcant’ was added deliberately, indicating that
the presence of a minute extent of residual activity, such as the
presence of a tender joint or residual swollen but painless joint,
or residual axial pain that does not appear to relate to inﬂamma-
tion, would still be compatible with remission. On the other
hand, the committee wished to have a stringent deﬁnition of
remission which would not allow signiﬁcant residual disease
activity, such as several swollen joints or signiﬁcant back pain,
even if dramatically improved by therapy, to be called remission.
Also, this bullet point speaks of ‘clinical remission’ indicating
that clinical rather than imaging measures should be used to
deﬁne remission, at least currently. In this respect it should be
noted that MRI shows evidence of inﬂammation in AS and that
a negative MRI can be regarded as imaging remission; however,
the relationship between clinical and imaging remission still
needs to be elaborated. Statement 3, which like the previous
ones is based on expert opinion, received approval by 83% of
the committee members and a SoR of 9.0±1.4.
4. Low disease activity/MDA may be an alternative treatment
target (LoE: 5; GoR: D)
While remission (inactive disease) constitutes an ideal goal,
clinical practice, stringently as it was deﬁned in bullet point
number 3 it may be difﬁcult to achieve in many patients, espe-
cially those with established/long-standing disease. Indeed,
patients with axSpA with longer disease duration are less likely
to attain partial remission than those with early disease.72 38
Thus, while remission is the ultimate and an ideal goal, low
disease activity constitutes a useful alternative in the opinion of
the task force, since it is assumed that physical function and
quality of life may not be much worse than in remission and
progression of structural damage, while possibly not halted,
would be minimal. Indeed, as included in the bullet point, low
disease activity can also be regarded as ‘MDA’. Thus, minor
residual signs and symptoms may still exist differentiating this
state from inactive disease. Importantly, by stating that low
disease activity is an alternative goal to remission, the committee
also clearly implies that any other, higher state, even moderate
disease activity, would not be acceptable and its presence should
elicit therapeutic adaptations. More research will be needed to
provide information on the optimal time point for achieving the
treatment target. However, given that in clinical trials of AS
maximal improvement was achieved between week 12 and week
24 regarding all outcome measures including ASAS partial
remission4 73 74 and that similar observations have been made in
PsA,2 75 76 a maximum of 6 months for reaching the treatment
target of low disease activity or remission seems appropriate,
but it is advisable to adapt therapy earlier if no signiﬁcant reduc-
tion in disease activity is observed within 3 months. Recently,
thresholds for disease activity states including inactive disease
(equivalent to remission) have been deﬁned for axSpA using the
ASDAS,12 and ASAS deﬁnition of partial remission is also avail-
able67; a measure of MDA has been developed for PsA which is
beginning to be used in clinical trials.77 78 Additional research
in this respect will be required, especially for PsA and peripheral
SpA. This item was accepted as deﬁned by 79% of the partici-
pants and received a SoR of 9.4±0.9.
5. Disease activity should be measured on the basis of clinical
signs and symptoms, and APRs (LoE: 5, GoR: D).
Traditionally, given that the spine is not as accessible to phys-
ical examination of signs of inﬂammation like a peripheral joint,
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disease activity in axSpA has been evaluated by employing the
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
which comprises only patient reported variables related to
symptoms of the disease. However, axSpA is an inﬂammatory
disease with involvement of various inﬂammatory cells and
cytokines.79 80 Indeed, inhibition of TNF is one of the main-
stays of treatment today, leading to relief of symptoms, and
inhibition of prostaglandin synthesis can reduce clinical symp-
toms, and retard progression of structural changes62 63; this
appears to be particularly prominent in patients with elevated
APRs, and the latter seem to be associated with progression of
syndesmophyte formation.70 81 82 Consequently, disease activity
assessment during follow-up and in the course of targeting a
good outcome should comprise the assessment of clinical
aspects of the disease as well as laboratory abnormalities, that is,
APR measurement. This can be done separately by looking at
for example, BASDAI and c-reactive protein (CRP), or by using
a measure that comprises both aspects, such as ASDAS.11 Along
the same line, PsA as an inﬂammatory and potentially destruc-
tive joint disease should be followed using measures that relate
to the joints and the serological inﬂammatory response; these
are contained in RA-related composite measures of disease activ-
ity, such as Disease Activity Score (DAS), DAS28 and Simpliﬁed
Disease Activity Index (SDAI), but also in the Disease Activity in
PsA and the psoriatic arthritis disease activity score.13 The
current recommendation does not relate to systemic features of
SpA, but solely to the musculoskeletal manifestations. For sys-
temic features, other measures are needed and, according to the
EULAR recommendations for treatment of PsA,18 this should be
done in collaboration with respective specialists.
Recommendation 5 received approval by 97% of participants
and the SoR amounted to 9.4±1.1.
6. The choice of the measure of disease activity and the level of
the target value may be inﬂuenced by considerations of comorbid-
ities, patient factors and drug related risks (LoE: 5; GoR: D)
Patients with chronic musculoskeletal diseases are frequently
also suffering from comorbidities that (1) may be related to the
overall spectrum of the disorder (such as IBD, uveitis or psoria-
sis), (2) may occur as a consequence of chronic inﬂammation
(such as cardiovascular disease), (3) may be related to therapy
(such as gastric ulcer or infection), or (4) just may occur con-
comitantly by chance. The presence of such comorbidities may
alter the level of the treatment target, since the risk of aggravat-
ing the comorbid condition may outweigh the beneﬁt conveyed
by more intensive therapy to achieve the treatment target of the
musculoskeletal manifestations. Further, the choice of follow-up
measure may have to be changed under certain circumstances.
For example, a concomitant disease which raises pain levels or
APRs may inﬂuence the result of measuring disease activity.
Likewise, when following patients on therapies that affect the
APRs independently of clinical beneﬁt one may have to recon-
sider the choice of a measure that contains an APR. Therefore,
this point focuses on the application (and sometimes restricted
applicability) of particular disease activity measures. This recom-
mendation was approved by 97% of the task force members
and received a SoR of 9.4±1.0.
7. Once the target is achieved, it should ideally be maintained
throughout the course of the disease (LoE: 5; GoR: D)
It is clear that no patient’s successfully targeted disease activ-
ity state should deteriorate during follow-up, since reactivation
of disease may again lead to reduced quality of life and disabil-
ity. There is evidence that on demand NSAID therapy, in con-
trast to regular NSAID treatment, is associated with progression
of radiographic changes in AS63 and that stopping TNF-blocker
therapy will lead to reactivation of AS83 and PsA.84 While the
present consensus statement is not designed to provide recom-
mendations on therapies with particular agents but rather on
treatment strategies, the task force nevertheless points to the
importance of maintaining the targeted therapeutic state once
achieved and advises against stopping a successful therapy based
on the available evidence. However, it has not yet been studied
sufﬁciently if dose reduction or expansion of treatment intervals
allows maintaining a good clinical state. Approval was given
by 90% of the task force’s members and the SoR amounted
to 9.4±0.8.
8. The patient should be appropriately informed and involved
in the discussions about the treatment target, and the risks and
beneﬁts of the strategy planned to reach this target (LoE: 5,
GoR: D)
While this statement has already been partly covered in the
overarching principles, it was felt important to also raise this
point in the context of the actual recommendations to bolster
the importance of interaction between health professionals and
their patients in all regards: setting and agreeing on the treat-
ment target, discussing the strategies available to reach that
target and the time it may take to attain it, and laying out the
beneﬁts and risks of the recommended treatment and consider
the totality of clinical disease manifestations (including the
extramusculoskeletal ones) and of comorbidities. This point also
comprises the need to discuss steps to be taken if the treatment
target is not achieved, such as adjustment of or switch to a new
therapy. In this respect patient education programmes or book-
lets may provide additional helpful means. This item was
approved by 81% of the participants and the SoR was 9.8±0.5.
9. Structural changes, functional impairment, extra-articular
manifestations, comorbidities and treatment risks should be con-
sidered when making clinical decisions, in addition to assessing
measures of disease activity.
This point is focused on considerations involved in thera-
peutic decision making. Although the last part of this recom-
mendation emphasises the importance of regular assessment of
disease activity with appropriate measures (see items 5 and 6),
the ﬁrst part suggests taking into account results of other investi-
gations for treatment decisions, such as by imaging (especially
structural changes in PsA), physical function and extra-articular
manifestations. The latter comprise enthesitis or dactylitis as
well as extramusculoskeletal disease. This is of importance,
since treatment approaches to PsA will differ in the presence of
enthesitis compared with patients who do not suffer from
entheseal affection.18 Moreover, organ disease, such as lung
involvement, aortitis, intestinal or skin manifestations as well as
uveitis, may require involvement of other specialists (see over-
arching principle B). In particular uveitis can present across the
spectrum of SpA and may reﬂect disease activity, and inﬂamma-
tory bowel disease and psoriatic skin involvement must be con-
sidered in the respective disorders and do not strongly correlate
with the degree or extent of musculoskeletal involvement. Risks
and comorbidities are also reiterated here in the context of
treatment decisions; before they were indicated with respect to
the choice of measures of disease activity (see recommendation 6)
and in relation to patient information (item 8). This recommen-
dation achieved 100% agreement and a SoR of 9.5±0.8.
Disease speciﬁc recommendations
As indicated above, items 10 and 11 have been formulated spe-
ciﬁcally for axSpA, PsA and peripheral SpA to account for the
differences between certain characteristics of the different
spondyloarthritides.
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Axial SpA (including AS)
10. Validated composite measures of disease activity such as
BASDAI plus APRs or ASDAS, with or without measures of func-
tion such as Bath Ankylosing Spondylitis Functional Index
(BASFI), should be performed and documented regularly in
routine clinical practice to guide treatment decisions; the fre-
quency of the measurements depends on the level of disease
activity.
This item is an expansion of recommendation numbers 5 and 9.
It mentions those disease activity measures which have been
repeatedly validated and are already in use in contemporary
clinical trials. In line with recommendation 5, when BASDAI is
employed, an APR, such as CRP or erythrocyte sedimentation
rate, should also be determined. The ASDAS already comprises
such a measure among its components.12 In addition, this rec-
ommendation also suggests the use of a particular functional
measure, but other validated measures can also be applied
(therefore the tem ‘such as’). With highly active disease,
follow-up examinations will have to be more frequent than with
inactive disease/remission. Moreover, the recommendation
requests documentation of the measured results. Among task
force members, 88% approved this item and SoR amounted to
9.3±1.0.
11. Other factors such as axial inﬂammation on MRI, radio-
graphic progression, peripheral musculoskeletal and extra-
articular manifestations, may also be considered when setting
clinical targets.
Again, this recommendation expands item 9, but speciﬁcally
mentions MRI as a highly valuable imaging method for the
potential follow-up of axSpA. Likewise, non-axial disease mani-
festations will inﬂuence not only the therapeutic approach but
have to be considered when setting treatment targets. Approval
was voted for by 88% of the members and the SoR was 9.3±0.8.
Peripheral SpA
10. Quantiﬁed measures of disease activity, which reﬂect the
individual peripheral musculoskeletal manifestations (arthritis,
dactylitis, enthesitis) should be performed and documented regu-
larly in routine clinical practice to guide treatment decisions; the
frequency of the measurements depends on the level of disease
activity.
This recommendation, while expanding items 5, is here spe-
ciﬁcally tailored to peripheral SpA, such as ReA, IBD arthritis or
former ‘undifferentiated’ peripheral SpA. Measures of disease
activity are available and have been validated for the arthritis
component of ReA9 and there exist measures for dactylitis and
enthesitis which have not been primarily developed for periph-
eral SpA, but rather for PsA or AS.85–87 While they will have to
be validated in peripheral SpA, they can be assumed useful for
clinical practice until proven otherwise. Also this recommenda-
tion calls for documentation of the measured results. Of the par-
ticipants, 100% approved this item and the SoR score achieved
was 9.3±0.9.
11. Other factors such as spinal and extra-articular manifesta-
tions, imaging results, changes in function/quality of life, as well
as comorbidities may also be considered for decision.
This item reiterates and expands recommendation 9 and
achieved 100% approval; the SoR was 9.4+0.8.
Psoriatic arthritis
10. Validated measures of musculoskeletal disease activity (arth-
ritis, dactylitis, enthesitis, axial disease) should be performed
and documented regularly in routine clinical practice to guide
treatment decisions; the frequency of the measurements depends
on the level of disease activity; cutaneous manifestations should
also be considered.
Speciﬁc mention of skin disease tailors this recommendation
to PsA, although skin may also be involved in axial and periph-
eral SpA. Further, in addition to arthritis, dactylitis and enthesi-
tis, axial disease assessment is speciﬁcally brought forward here.
Finally, a reminder is provided that the results of the various
measures (and also the treatment target) should be documented.
Clearly, with highly active disease patients should be seen fre-
quently, such as monthly to every 3 months, while with low
disease activity or remission, follow-up examinations may be
done only every 6–12 months. However, skin involvement also
has to be taken into account. The voting achieved 92% approval
and the SoR amounted to 9.4±0.8.
11. Other factors such as spinal and extra-articular manifesta-
tions, imaging results changes in function/quality of life, as well
as comorbidities may also be considered for decision.
As for the other disease entities, this last recommendation
expands item 9 and also the preceding one by reiterating the
importance of comorbidities, and axial and soft tissue manifes-
tations of PsA in the course of making treatment decisions.
Approval was granted by 100% of the participants and the SoR
amounted to 9.3±1.0.
A ﬁnal anonymous vote on whether the task force members
felt inﬂuenced by the fact that support for this activity was pro-
vided by a company, the result was 0.4±1.3 (0 meaning no and
10 meaning heavy inﬂuence), indicating that the participants felt
negligibly inﬂuenced.
Research agenda
Since none of the recommendations is based on evidence, the
research agenda has to comprise the search for evidence for all
of them. However, beyond mere therapeutic aspects, insights
into the relationships between individual musculoskeletal mani-
festations, damage and disability are still incomplete especially
for the peripheral SpA, including PsA. Table 2 lists a research
agenda as mentioned during the task force’s meetings.
DISCUSSION
Recommendations to treat axSpA and PsA have been developed
over the recent years.17–19 However, none of these addressed a
clear therapeutic target and a strategy to reach this target. This
has now been done in the present set of recommendations, and
additional strategic aspects of treatment approaches are pre-
sented. Thus, the present consensus on treatment targets and
general treatment approaches complements the published man-
agement recommendations,17–20 but a notable difference is the
absence of suggestions or recommendations regarding a particu-
lar drug in any of the overarching principles or individual
recommendations.
Treatment recommendations should usually be based on evi-
dence. However, where evidence is missing, expert opinion has
to come into play. The recommendations presented here are not
based on hard evidence, because strategic therapeutic trials, in
which therapy was consistently adapted to reach a prespeciﬁed
treatment target and compared with a non-steered approach, as
performed in RA,88 89 are currently not available for axSpA,
peripheral SpA or PsA, and other pertinent literature is scarce.
While a SLR has provided indirect evidence from clinical trials
which targeted speciﬁc endpoints37 and thus supplied some
information towards the work of the task force, the individual
recommendations can only be regarded as expert opinion (con-
sensus) and therefore call for more research in the ﬁeld.
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So why then were the recommendations developed now
rather than waiting for more evidence? Because the deﬁnition of
a treatment target and strategy is timely at present in light of
two major aspects: (1) a ﬁeld like that of SpA should not stay
behind other disease areas which have already deﬁned their
targets years to decades ago, when at least indirect evidence for
the beneﬁt of attaining certain treatment targets is available; and
(2) the tremendous therapeutic advances of the past decade
have greatly improved the chances of achieving good outcomes
and, therefore, setting stringent treatment milestones has
become a reality which should not be concealed. Moreover, in
the course of its initial discussions on this issue, the task force
felt that with these advances and the concomitant formulation
of a research agenda, investigations towards providing respective
evidence could be fostered and accelerated. Importantly, this
view was shared among all task force members, which com-
prised patients and an international group of physicians with
expertise in SpA.
At all three steps of this activity, which included initial discus-
sions by the steering committee, formulation of recommenda-
tions by an expanded working group and development of
treatment recommendations for all three entities, axSpA, periph-
eral SpA and PsA, unanimous agreement was attained.
Moreover, all items achieved strong consensus in an anonymous
voting process, with the lowest result being a mean of 9.0 on a
scale of 0–10, indicating that the task force stood quite united
behind the recommendations.
The complexity of the current endeavour resulted from the
heterogeneity of the diseases covered. After long discussions and
the intermediate development of more than one document, it
was decided to produce a single set of recommendations for
axSpA, peripheral SpA and PsA, in line with recent criteria for
classiﬁcation of SpA.15 Five overarching principles and nine
recommendations were developed in common for all forms of
SpA, including PsA. Only two recommendations were separately
produced for axSpA, peripheral SpA and PsA, although their
general scope was still very similar and differences only very
subtle. The overall activity was partly inﬂuenced by the treat-to-
target recommendations for RA.32
Several of the recommendations stand out in their import-
ance, while others can be seen as supportive or operational.
A call for remission or inactive disease became item 1, because
this was regarded the foremost treatment target. Indeed, we can
anticipate that reducing inﬂammation and disease activity to the
minimum is optimal for the patients, at least for their quality of
Table 2 Research agenda
Topics Specific questions
Composite activity measures
(mainly PsA and peripheral SpA)
Validation where needed, definition of
disease activity states and response
categories
Remission definition Is it important that all clinical domains of
axial SpA, peripheral SpA or PsA are in
remission or is it sufficient to define some of
them?
Treatment target Is there a difference in long-term outcome
when comparing remission with low disease
activity?
Activity and damage What is the progression of joint damage in
different disease activity states in PsA?
Disease duration Are there differences in responsiveness and
thus differences in attaining certain targets
with different disease duration in PsA?
Treatment to target There is a need to design therapeutic trials
that compare steered therapy aiming at
remission or low disease activity with
non-steered treatment (like TICORA)88
Axial involvement in PsA Do spinal and peripheral involvements
respond similarly or differently?
Enthesitis, dactylitis More data need to be attained on the
response of dactylitis or enthesitis to different
therapies
Care by rheumatologist Is care of axial SpA, peripheral SpA or PsA by
a rheumatologist advantageous for outcomes
when compared with care by
non-rheumatologists?
Maintenance of response How can response be maintained? Can the
dose of the therapy employed be reduced or
the interval of applications be expanded and
outcome maintained?
Patient Is outcome different when patients are
informed in a structured way when compared
with more general means of information?
PsA, psoriatic arthritis; SpA, Spondyloarthritis.
Figure 1 Algorithm to treat
spondyloarthritis (SpA) to target. The
algorithm depicts the main (remission)
and the alternative target (low disease
activity), the need to adapt therapy if
the target is not reached, the
requirement to use measures that
reﬂect clinical activity and acute phase
reactants and the sustainment of
remission (developed in consideration
of the ﬁgure for the rheumatoid
arthritis algorithm).32
Smolen JS, et al. Ann Rheum Dis 2014;73:6–16. doi:10.1136/annrheumdis-2013-203419 13
Recommendation
life. However, the members were aware that remission may not
be achievable in all patients and, therefore, formulated an alter-
native treatment target, especially for patients with long-standing
disease, namely low disease activity (recommendation 4).
Importantly, this acknowledgement indicates that disease activity
states other than remission or low disease activity constitute
unacceptable clinical states, unless justiﬁed because of other
reasons, such as comorbidity (items 6, 9 and 11). Importantly,
while validated measures of disease activity are available for PsA
and ReA, disease activity states have not yet been sufﬁciently
deﬁned, contrasting the situation in AS. Another complexity
relates to the necessity to use measures that reﬂect the individual
manifestations of a patient which in some instances may involve
assessment of peripheral joint disease, axial involvement, dacty-
litis and enthesitis. To identify an individual treatment goal can
in itself be seen as an important part of a treatment strategy
when an intervention is initiated and should be accompanied by
a monitoring programme. It is also important that the agreed
goal is documented in the records of the patient.
Patient involvement in deﬁning the treatment target and selec-
tion of therapies based on their risks and beneﬁts was deemed
so important, that it is stated in the ﬁrst overarching principle
and additionally in one of the recommendations.
As indicated above, given the small evidence base, the research
agenda is of utmost importance. Research activities should focus
on strategic therapeutic trials, and on addressing missing infor-
mation, such as the deﬁnition of disease activity states in PsA.
The recommendations are summarised in a simpliﬁed form in
an algorithm presented in ﬁgure 1. Like most types of recom-
mendations, it will be necessary to revise the current document
in due course, presumably in about 4 years or 5 years or earlier,
when signiﬁcant evidence accumulates regarding the individual
points of the recommendations. The task force hopes for an
expansion of high quality research activities that either allow
conﬁrmation or modiﬁcations of its conclusions.
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